The APA Task Force report on benzodiazepine dependence, toxicity, and abuse
Open accessThe DOI matches its Crossref record.
Abstract
I 1987 the American Psychiatric Association, recognizing the need for guidelines for prescribing benzodiazepines, established a task force to gather and report on the available information regarding these widely prescribed drugs. The report has recently been published by APA ( 1 ) and is strongly recommended to all psychiatrists. The report represents a group consensus; agreement was not unanimous on all points. The work of the task force was supported entirely by APA funding. Although many adults may take an occasional benzodiazepine, two-thirds of therapeutic use is for 60 days or less. Small but substantial numbers of adults have been taking benzodiazepines daily (or nightly) for 1 year or more. Over a period of many years, these adults represent 1.65% of the population, and they fall into four distinct groups. The first group comprises older, medically ill patients who are taking other medications. Benzodiazepines are usually prescribed for these patients by a nonpsychiatrist. The second group comprises psychiatric patients with panic or agoraphobic disorders. In the first and second groups, benzodiazepines are seldom abused, doses are not escalated, and patients as well as their physicians attest to the therapeutic necessity for the medication. The third group comprises psychiatric and general medical patients with recurrent dysphoria. Because of the vagueness and chronicity of symptoms in this group, the indications for long-term use are less certain than those for the first two groups. Occasional patients may escalate their doses, and abuse of higher doses in combination with alcohol or other abused substances may occur. The fourth group is composed of patients with chronic sleep disorder. Although research data do not consistently support the long-term hypnotic efficacy of benzodiazepines when taken for more than 30 consecutive nights, some patients claim that they cannot sleep without a benzodiazepine at bedtime. To what extent regular nightly benzodiazepines are preventing rebound insomnia or actually are treating a chronic sleep disturbance is not known. Therapeutic use of benzodiazepines can be associated with potential hazards to the patient. True physical dependence can arise from chronic therapeutic use, defined by the appearance of a constellation of discontinuance symptoms following abrupt withdrawal. These symptoms can be divided into three categories: rebound, recurrence, and withdrawal. Rebound symptoms, the first to appear after drug termination, are the mirror image of the effects of the drug (worse anxiety, insomnia, and restlessness) and may be severe enough to cause the patient to return to the drug. For some short-half-life benzodiazepines, rebound symptoms may appear between doses, so that patients become dependent and are aware when the next dose will be needed. Other discontinuance symptoms, usually appearing after rebound, may be identical to the symptoms for which the drug was originally prescribed and confuse both the patient and the clinician. It is often difficult to determine whether these symptoms represent a recurrence of the original reasons for the benzodiazepine prescription, a manifestation of drug discontinuance, or both. Withdrawal symptoms that were not present when the drug was initially prescribed make up the third
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Park, T. W., Saitz, R., Ganoczy, D., Ilgen, M. A., & Bohnert, A. S. B. (2015) · BMJ · doi:10.1136/bmj.h2698 · Cited by 579
Psychoactive drug abuse in older adults
Simoni-Wastila, L., & Yang, H. K. (2006) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2006.10.002 · Cited by 306
Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives
Guina, J., & Merrill, B. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7020017 · Cited by 253
“BZD toxicity in the elderly can cause cognitive impairment even with short-term therapeutic doses [11].”
BackgroundInfluentialChronic benzodiazepine usage and withdrawal in insomnia patients
Poyares, D., Guilleminault, C., Ohayon, M. M., & Tufik, S. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2003.10.003 · Cited by 94
Kroll, D. S., Nieva, H. R., Barsky, A. J., & Linder, J. A. (2016) · Journal of General Internal Medicine · doi:10.1007/s11606-016-3740-0 · Cited by 94
Metadata
- Venue
- American Journal of Psychiatry
- Published
- 1991-02-01
- Volume
- 148
- Issue
- 2
- Pages
- 151-152
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2402149294
- Cited by
- 101
- References
- 0
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The APA Task Force report on benzodiazepine dependence, toxicity, and abuse. https://app.cochat.ai/papers/10.1176/ajp.148.2.151
- The paper
- The APA Task Force report on benzodiazepine dependence, toxicity, and abuse. (1991). American Journal of Psychiatry. https://doi.org/10.1176/ajp.148.2.151
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.